



## Javelin Pharmaceuticals Quarterly Conference Call Invitation

CAMBRIDGE, Mass., Mar 05, 2009 (BUSINESS WIRE) -- Javelin Pharmaceuticals, Inc. (NYSE Alternext: JAV) announced today that Martin J. Driscoll, Chief Executive Officer and Stephen J. Tulipano, CPA, CFO, will host its regular quarterly earnings conference call covering the fourth quarter and full year 2008 results. The call will be held Thursday, March 12, 2009 at 8:30 a.m. EDT.

The Company invites all interested parties to participate. The call will be simulcast live over the internet through the following URL: <http://ir.javelinpharmaceuticals.com/events.cfm> and will be archived on the Company's website at [www.javelinpharmaceuticals.com](http://www.javelinpharmaceuticals.com).

### CONFERENCE CALL INFORMATION

Javelin Pharmaceuticals, Inc. Fourth Quarter & Full Year 2008 Conference Call

March 12, 2009 at 8:30 A.M. EDT

Those Interested in participating in the call should dial 877-874-1571 within the United States or 719-325-4800 internationally

About Javelin Pharmaceuticals, Inc.

With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the acute pain management market. The Company has one marketed drug in the UK and three drug candidates in US Phase 3 clinical development. For additional information about Javelin, please visit the Company's website at <http://www.javelinpharmaceuticals.com>.

### Forward Looking Statement

This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies.

JAV-E

SOURCE: Javelin Pharmaceuticals, Inc.

Javelin Pharmaceuticals, Inc.  
Investor Relations & Media  
Rick Pierce, 617-349-4500  
VP Investor Relations  
[rpierce@javelinpharma.com](mailto:rpierce@javelinpharma.com)  
or  
Corporate Communications  
June Gregg, 617-349-4500  
[jgregg@javelinpharma.com](mailto:jgregg@javelinpharma.com)

Copyright Business Wire 2009